Upcoming Events
August 2026
Biosecurity Simulation Exercise (BSX 2026)
This tabletop simulation exercise aims to enhance inter-sectoral and inter-disciplinary preparedness for laboratory biosafety and biosecurity and deliberate biothreat events.
- Course
Past Events
September 2023
Climate Change and Health: Panel Discussion on Impacts, Adaptation and Mitigation within the Health Sector
Climate change is currently the greatest threat to human health and requires innovative solutions to support health and environmental goals. This panel will examine the impacts of climate change on health, adaptation measures by health systems and how the health sector can contribute to mitigating climate change by reducing emissions. Panellists will discuss firsthand experience responding to climate-driven cholera epidemics in Bangladesh, planning and supporting policies for malaria elimination in the face of climate change and developing a world-class net zero emission health service in the United Kingdom. The programme will include a moderated discussion amongst panellists, followed by a Q&A with audiences.
August 2023
Deconvolution of bulk RNA-seq reveals cell-type specificity mechanism in Alzheimer’s disease
Bulk tissue transcriptomic profiles cannot reflect the functional heterogeneity across cell types. We here propose a new empirical Bayes method (EPIC-unmix), that integrates sc/snRNA-seq reference and bulk RNA-seq data from target samples to enhance cell-type-specific (CTS) expression inference in target samples. We applied EPIC-unmix to deconvolute ROSMAP bulk RNA-seq data from prefrontal cortex samples. Downstream analysis of CTS gene expression, including identification of CTS differentially expressed (DE) genes, CTS eQTL analysis and functional annotations in the corresponding cell type for DE genes, suggested IKZF1 as a risk gene for Alzheimer’s disease functioning in microglia.
July 2023
Comparative effectiveness clinical trials in infectious diseases research – pitfalls and novel approaches
Comparative effectiveness trials compare different established standards of care, for example different antibiotic choices or durations. The non-inferiority trial design is commonly used in infectious diseases research, but there are several methodologic issues and potential pitfalls that need to be carefully thought about when conducting a non-inferiority trial. Novel approaches such as ordinal outcomes and the DOOR/RADAR design may be useful alternatives, but come with their own issues.
Staff Research Rounds – Prof Ashley Akbari & Dr Pete Arnold
You are cordially invited to the ON-SITE SSHSPH Staff Research Round. We look forward to your attendance and we hope for an interesting discussion.
Precision Public Health Asia 2023 Conference
The conference will explore current and future strategies related to precision public health, covering genomics, population health, digital health, big data and artificial intelligence – and how they can benefit public health in the developed and developing worlds.
Staff Research Rounds – Dr Teerawattananon & Dr Isaranuwatchai
There has been lots of debate regarding an optimum value of cost-effectiveness threshold around the world. Many governments, for examples, in the United Kingdom and Thailand receive challenges whether the current CET used are too low and that their CET should be increased. To our knowledge, Thailand is the only country which has explicit CET and has increased the CET during the past 15 years. Therefore, Thailand is in a unique position to help answer the question of what happened when CET was increased. The findings from this study can assist in the discussion of whether and how CET values should be increased. Health Intervention and Technology Assessment Program (HITAP) in collaboration with Saw Swee Hock School of Public Health, National University of Singapore and the Hitotsubashi Institute for Advanced Study in Japan, was commissioned by the National Drug Subcommittee to answer the question of “What are the Impacts of Increasing Cost-effectiveness Threshold?” to assist in the discussion of whether or not Thailand’s current CET should be increased. The study objectives were to explore the impact of increasing cost-effectiveness threshold (CET) on the submitted drug price (published in economic evaluation reports) and the decision to include high-cost drugs in the National List of Essential Medicine (NLEM) in Thailand. Retrospective secondary data analysis using data from published economic evaluation reports being reviewed by the National Drug Subcommittee in the past 13 years.